SCHEMBL3086869

SCHEMBL3086869

Cc1ccc2nc(Cl)cn2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
DYRK1A Q13627 1/20 0.41
PDE10A Q9Y233 2/20 0.41
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
AHR P35869 4/20 0.37
RBP4 P02753 1/20 0.36
COMT P21964 1/20 0.35
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
PKM P14618 1/20 0.33
F2RL3 Q96RI0 1/20 0.33
DRD2 P14416 2/20 0.33
DRD4 P21917 2/20 0.33
DRD3 P35462 2/20 0.33
HTR1A P08908 1/20 0.33
ADRA1D P25100 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3921056 0.81 DYRK1A (0.58) KDM4EMEN1KMT2ADYRK1APDE10A
SCHEMBL756100 0.81 KDM4E (0.50) KDM4EDYRK1APDE10ASMN1; SMN2AHR
SCHEMBL26373829 0.78 DYRK1A (0.42) KDM4EMEN1KMT2ADYRK1APDE10A
SCHEMBL7895997 0.76 DYRK1A (0.41) KDM4EMEN1KMT2ADYRK1ANPC1
SCHEMBL7889606 0.76 DYRK1A (0.41) KDM4EMEN1KMT2ADYRK1ANPC1
SCHEMBL25104909 0.76 DYRK1A (0.41) KDM4EMEN1KMT2ADYRK1APDE10A
SCHEMBL12673757 0.76 DYRK1A (0.41) KDM4EMEN1KMT2ADYRK1ANPC1
SCHEMBL477109 0.76 DYRK1A (0.53) KDM4EMEN1KMT2ADYRK1APDE10A
SCHEMBL2066163 0.76 PDE10A (0.50) KDM4EDYRK1APDE10AAHRDRD2
SCHEMBL3342789 0.76 PDE10A (0.39) KDM4EDYRK1APDE10AAHRDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870638-B2 Pyridazinone compound or its salt, and herbicide containing it ISHIHARA SANGYO KAISHA, LTD. (JP) 2020-12-22 US disclosed
US-20200172517-A1 PYRIDAZINONE COMPOUND OR ITS SALT, AND HERBICIDE CONTAINING IT ISHIHARA SANGYO KAISHA, LTD. (JP) 2020-06-04 US disclosed
US-8946222-B2 Phenoxymethyl heterocyclic compounds FORUM PHARMACEUTICALS INC. (US) 2015-02-03 US disclosed
US-20130143888-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS ENVIVO PHAMACEUTICALS, INC. (US) 2013-06-06 US disclosed
EP-1930331-B1 METHOD FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND SUMITOMO CHEMICAL CO (JP) 2013-03-13 EP disclosed
US-8334379-B2 Process for producing imidazo[1,2-b]pyridazine compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-18 US disclosed
US-20100234597-A1 PROCESS FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-16 US disclosed
EP-1930331-A1 METHOD FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10870638-B2 Pyridazinone compound or its salt, and herbicide containing it H1-0, H1-4, H1-3 KDM4E 1092/4885MEN1 4130/4885KMT2A 313/4885
US-20130143888-A1 PHENOXYMETHYL HETEROCYCLIC COMPOUNDS PDE3A, PDE2A, PDE5A KDM4E 559/4885MEN1 1513/4885KMT2A 1618/4885
US-20100234597-A1 PROCESS FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND CYP1B1, CYP4Z1, CYP2J2 KDM4E 2589/4885MEN1 3138/4885KMT2A 1643/4885
US-20200172517-A1 PYRIDAZINONE COMPOUND OR ITS SALT, AND HERBICIDE CONTAINING IT H1-0, H1-4, H1-3 KDM4E 1092/4885MEN1 4130/4885KMT2A 313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.